Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Stanford University
Columbia University
Wake Forest University Health Sciences
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Jazz Pharmaceuticals
Istari Oncology, Inc.
Mayo Clinic
Washington University School of Medicine
University of Oklahoma
Children's Hospital Medical Center, Cincinnati
University of Pittsburgh
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Florida
National Cancer Institute (NCI)
Washington University School of Medicine
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Virginia Commonwealth University
Radiation Therapy Oncology Group
Celgene
Memorial Sloan Kettering Cancer Center
Candel Therapeutics, Inc.
Exelixis
Novartis
Novartis
Duke University
TVAX Biomedical
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Duke University
Mayo Clinic
Karyopharm Therapeutics Inc
Medicenna Therapeutics, Inc.
Indiana University
Eisai Inc.
NYU Langone Health
University of Florida
Northwestern University